Konruns(SH:603590) 智通财经网·2025-09-05 07:44Core Viewpoint - Kangchen Pharmaceutical's innovative drug KC1036 has been included in the "Children's Antitumor Drug Development Encouragement Pilot Program (Star Program)" by the National Medical Products Administration's Drug Evaluation Center, highlighting its potential in pediatric oncology [1] Group 1: Product Development - KC1036 is a class 1 innovative chemical drug developed independently by the company, with global intellectual property rights [1] - The drug exhibits antitumor activity by inhibiting multiple targets such as VEGFR2 and AXL [1] - Over 300 adult cancer patients have participated in clinical studies for KC1036, showing significant antitumor activity and good safety and tolerability across various indications, including gastrointestinal and thymic tumors [1] Group 2: Regulatory Recognition - KC1036 is the first innovative drug to be included in the "Star Program," indicating recognition from the Drug Evaluation Center regarding its innovation and potential benefits for pediatric patients with Ewing's sarcoma [1] - The company plans to actively report progress and results related to the implementation framework required by the Drug Evaluation Center to advance clinical research and market entry for KC1036 in the pediatric Ewing's sarcoma field [1]